Orexin and Danavorexton: The Wakefulness Drug Pipeline That Could Treat Sleep Apnea Sleepiness
Orexin Drugs and Sleep Apnea Daytime Sleepiness: What the Pipeline Really Means
A clear, EU-focused look at danavorexton, oveporexton, and the wake-promoting drugs being studied for the sleepiness that lingers despite treatment.
Orexin Drugs and Sleep Apnea Daytime Sleepiness: The Short Answer
Orexin drugs are a new class of medicines designed to switch on wakefulness in the brain, and researchers are now testing whether they can ease orexin drugs sleep apnea daytime sleepiness in people who stay tired even after their breathing is treated. Orexin (also called hypocretin) is a brain chemical that keeps you awake; drugs that activate its receptors aim to top up that signal. Early results are promising for the symptom, but none are approved for obstructive sleep apnea (OSA) in Europe yet.
This matters because a large share of treated patients still feel sleepy. That gap is exactly why the science is moving so fast, and why it helps to separate "a future pill for the sleepiness" from "treating the breathing problem tonight." For more on which medicines are actually available, see our guide to sleep apnea medications in 2026, and our explainer on recognizing daytime drowsiness from sleep apnea.
An estimated 175 million Europeans have obstructive sleep apnea, with about 90 million having moderate-to-severe disease (Lancet Respiratory Medicine global burden estimate, presented at ERS Congress, 2019). With numbers that large, even a symptom-targeting drug could help millions, but only as one piece of care.
- Orexin agonists aim to restore wakefulness, not to fix the airway obstruction.
- No orexin drug is approved for OSA in the EU as of 2026.
- They are studied as adjuncts for residual sleepiness, not as a CPAP replacement.
What Orexin Is and How It Keeps You Awake
Orexin is a signaling chemical made by a small cluster of neurons in the hypothalamus, the brain's master switch for sleep and wake. When these neurons fire, they release orexin onto two docking points called receptors, named OX1R and OX2R. Activating the OX2R receptor is the strongest driver of staying awake and alert.
In narcolepsy type 1, the orexin neurons are destroyed, so the wake signal collapses and people fall asleep suddenly. Most people with sleep apnea are different: their orexin system is intact, but fragmented breathing and poor sleep quality leave them drowsy by day. That distinction shapes the whole pipeline.
Agonists Versus Antagonists
The words sound similar but do opposite jobs. An orexin agonist switches the receptor on to promote wakefulness, which is what danavorexton and oveporexton do. An orexin antagonist blocks the receptor to encourage sleep, which is how some insomnia drugs already on the market work. For sleepy sleep apnea patients, researchers want the agonist side.
- Orexin is a natural wake-promoting brain chemical acting through OX1R and OX2R.
- The OX2R receptor is the main switch for staying awake.
- Sleep apnea patients usually have a working orexin system, unlike narcolepsy type 1.
Why People Stay Sleepy Despite Treatment
Residual excessive daytime sleepiness is feeling persistently drowsy even when sleep apnea therapy is working well and used regularly. It is one of the most frustrating problems in sleep medicine, because the breathing numbers look good while the person still struggles to stay awake at a desk or behind the wheel.
European data show this is common, not rare. In the European Sleep Apnea Database (ESADA), an Epworth Sleepiness Scale score above 10, the standard marker of excessive sleepiness, was present in 56% of CPAP-treated patients at baseline and still 28.2% at follow-up (ESADA, Frontiers in Neurology, 2021). Roughly one in four remained sleepy despite therapy.
Estimates vary by how strictly you define the problem. A French multicentre study found residual excessive daytime sleepiness in 12.0% of CPAP-treated patients, falling to 6.0% after excluding other causes such as depression, restless legs and narcolepsy (European Respiratory Journal, 2009). Either way, a real group stays tired, and that unmet need is what the orexin pipeline targets.
- Residual sleepiness means tiredness persists despite well-used therapy.
- European data put it at roughly 6% to 28% of treated patients depending on definition.
- It signals the symptom, not the airway, still needs attention.
Danavorexton and the First Sleep Apnea Evidence
Danavorexton, also known by its research code TAK-925, is an OX2R-selective orexin agonist and the first drug of its kind tested directly in sleep apnea patients with leftover sleepiness. It was given as an intravenous (IV) infusion, meaning through a vein rather than as a pill, which is the main practical limit of the early studies.
The key trial was a Phase 1b crossover study in 25 adults who had OSA and residual excessive daytime sleepiness despite adequate CPAP. Each person received a single nine-hour infusion of danavorexton 44 mg, 112 mg, or placebo on separate days, then their alertness was measured with the Maintenance of Wakefulness Test (MWT), a standard lab test of how long someone can stay awake.
The wakefulness improvement was large. Mean MWT sleep latency rose from 11.45 minutes on placebo to 33.57 minutes on the 44 mg dose and 39.62 minutes on the 112 mg dose, both highly significant at p<0.0001 versus placebo (Sleep Medicine, ScienceDirect, 2023). In plain terms, treated patients stayed awake roughly three times longer in the test.
What About Side Effects?
Tolerability mattered too. In the same trial of 25 randomized patients, 16 (64.0%) had treatment-emergent adverse events and 12 (48.0%) had treatment-related events, all mild or moderate (Sleep Medicine, 2023). No severe events were reported in this small, short study, but long-term safety in OSA remains unproven.
- Danavorexton tripled lab-measured wakefulness versus placebo in a small trial.
- Side effects were common but mild to moderate in this short study.
- It is IV-only, investigational, and not approved for OSA.
The Oral Pipeline: Oveporexton and Beyond
The bigger story is the shift from IV infusions to oral orexin agonists you could swallow. Oveporexton, research code TAK-861, is an oral OX2R-selective agonist that met all primary and secondary endpoints in the Phase 3 FirstLight and RadiantLight narcolepsy type 1 trials (Takeda, World Sleep 2025 data; New England Journal of Medicine, 2025). Regulatory submissions are expected from 2026 onwards.
That progress is real but narcolepsy-first. Oveporexton's pivotal data are in orexin-deficient narcolepsy, not in sleep apnea. Other oral candidates such as ORX750 and E2086 are also advancing through early trials. Whether any of them help non-orexin-deficient OSA patients with residual sleepiness must be proven in dedicated OSA studies, which are still early.
For Europe specifically, approval depends on the European Medicines Agency (EMA), and an OSA indication would require its own evidence package submitted to the EMA. So the honest timeline is: an oral orexin drug may reach narcolepsy patients first, with any sleep apnea use following later, if the trials succeed. To see how this fits other emerging medicines, read our analysis of the AD109 (Sulthiame) Phase 3 results.
| Drug | Type | Lead indication | OSA status (EU) |
|---|---|---|---|
| Danavorexton (TAK-925) | IV OX2R agonist | Residual EDS / narcolepsy | Investigational only |
| Oveporexton (TAK-861) | Oral OX2R agonist | Narcolepsy type 1 | Not studied for OSA approval |
| ORX750 | Oral OX2R agonist | Narcolepsy (early) | Investigational only |
| E2086 | Oral orexin agonist | Sleepiness disorders (early) | Investigational only |
- Oral orexin agonists are advancing, led by oveporexton in narcolepsy.
- Key regulatory submissions cluster around 2026, but for narcolepsy first.
- Sleep apnea use would need its own trials and EMA review.
Orexin Drugs and Sleep Apnea Daytime Sleepiness: Symptom Versus Cause
Here is the clarity the clinical papers rarely give a general reader: orexin drugs target the sleepiness symptom, not the obstruction. Even if approved one day, they would help only people whose airway is already managed and who still feel tired. They do nothing to keep the airway open during sleep.
That is why airway-focused options stay relevant. The Back2Sleep nasal stent is a soft silicone intranasal device that keeps the nasal airway open during sleep. It is CE-certified Class I, needs no prescription, no electricity, no noise and no tubing, and the starter kit includes four sizes to find your fit. It addresses the upstream mechanical cause of snoring and mild-to-moderate OSA.
So the two approaches are complementary, not competing. A future orexin pill might one day ease residual daytime sleepiness, while a device like Back2Sleep can help reduce airway obstruction tonight. Be clear on limits: Back2Sleep is for snoring and mild-to-moderate OSA, it is not a substitute for CPAP in severe OSA, and anyone with persistent daytime sleepiness should be evaluated by a sleep specialist.
| Approach | What it targets | Available now in EU? | Best for |
|---|---|---|---|
| Orexin agonists (future) | Daytime sleepiness symptom | No (investigational for OSA) | Residual EDS once airway is managed |
| CPAP | Airway obstruction | Yes (prescription) | Moderate-to-severe OSA |
| Back2Sleep nasal stent | Airway obstruction | Yes (no prescription) | Snoring, mild-to-moderate OSA |
| Weight and lifestyle | Underlying risk factors | Yes | All severities, as support |
- Orexin drugs would treat the sleepiness symptom, not the airway.
- Back2Sleep targets the mechanical cause of snoring and mild-to-moderate OSA now.
- It is not a CPAP replacement for severe OSA; see a sleep specialist for persistent sleepiness.
What Sleepy Patients Can Actually Do Today
While the pipeline matures, practical steps still help. The goal is to confirm the diagnosis, treat the airway, and only then chase residual sleepiness with a specialist's guidance. Studies suggest much daytime tiredness improves once the breathing is genuinely controlled.
1Get properly diagnosed
If you snore loudly or feel unrefreshed, ask for a sleep assessment. Diagnosis guides whether you have snoring, mild-to-moderate OSA, or severe disease needing CPAP.
2Treat the airway consistently
Use your prescribed therapy nightly, or consider a drug-free device for snoring and mild-to-moderate OSA. Consistent airway support is the foundation before targeting sleepiness.
3Support with lifestyle
Weight management, reduced evening alcohol, side sleeping, and a steady sleep schedule all lower airway risk and can sharpen daytime alertness.
4Reassess residual sleepiness
If tiredness lingers despite good therapy, return to a sleep specialist. They can rule out other causes and discuss approved wake-promoting options where appropriate.
- Diagnosis first, then consistent airway treatment, then symptom management.
- Lifestyle measures support every severity of sleep apnea.
- Persistent sleepiness on therapy warrants a specialist review.
What Back2Sleep Users Say
Frequently Asked Questions
What are orexin drugs and how do they treat daytime sleepiness?
Orexin drugs are medicines that activate the brain's orexin receptors, especially OX2R, to boost wakefulness signals. Orexin is a natural chemical that keeps you alert. Agonists like danavorexton switch these receptors on, helping people stay awake. They target the sleepiness symptom rather than the underlying cause of sleep apnea.
Can orexin agonists like danavorexton cure or replace CPAP for sleep apnea?
No. Orexin agonists target daytime sleepiness, not the airway obstruction that causes sleep apnea. They do nothing to keep the airway open during sleep, so they cannot cure the condition or replace CPAP. They are studied as adjuncts for residual sleepiness in patients whose breathing is already treated.
Is danavorexton (TAK-925) approved for obstructive sleep apnea?
No. Danavorexton is investigational and not approved for obstructive sleep apnea in Europe or elsewhere. Its sleep apnea evidence comes from one small Phase 1b crossover trial using a nine-hour intravenous infusion, not a take-home pill. Larger studies would be needed before any regulatory approval for OSA could be considered.
What is the difference between orexin agonists and orexin antagonists?
An orexin agonist switches the receptor on to promote wakefulness, which is what danavorexton and oveporexton aim to do. An orexin antagonist blocks the receptor to encourage sleep, which is how some insomnia medicines already on the market work. Sleepy sleep apnea patients are studied with agonists, not antagonists.
Why do some people still feel sleepy on CPAP (residual excessive daytime sleepiness)?
Residual sleepiness means tiredness persists even when therapy is used well and the breathing numbers look good. European ESADA data found an Epworth score above 10 in 28.2% of treated patients at follow-up. Causes include incomplete control, other conditions, or independent sleep disorders, so a specialist review is wise.
What is oveporexton (TAK-861) and when could it be available in Europe?
Oveporexton is an oral OX2R-selective orexin agonist that met all endpoints in Phase 3 narcolepsy type 1 trials. In Europe it would need European Medicines Agency (EMA) approval, with a regulatory submission expected around 2026. Its data are in narcolepsy, not sleep apnea, so any OSA use would follow later, only if dedicated trials succeed.
Are there pills to stay awake if you have sleep apnea?
Some approved wake-promoting medicines exist for residual sleepiness in treated sleep apnea, prescribed by specialists. Orexin agonists like danavorexton are not yet approved for this use in Europe. Any wake-promoting pill addresses only the symptom, so the airway must still be treated first with devices, CPAP, or lifestyle changes.
Do orexin wakefulness drugs have side effects?
Yes. In danavorexton's small Phase 1b sleep apnea trial, 64% of patients had treatment-emergent adverse events and 48% had treatment-related events, all mild or moderate. Long-term safety in sleep apnea is unproven because the studies are short and small. A specialist should weigh benefits and risks for each individual.
Ready for quieter nights? Discover the Back2Sleep starter kit and find the right fit for you.
Not sure if you are at risk? Take our sleep risk screening to find out in just a few minutes.
Want to learn how it works? Explore the Back2Sleep nasal stent designed for comfortable, effective relief.